BIO-TECHNE Corp Stock Nasdaq
Equities
US8783771004
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Jul. 01 | Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell Midcap Growth Index | CI |
Jul. 01 | Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 3000 Growth Index | CI |
Financials (USD)
Sales 2024 * | 1.16B | Sales 2025 * | 1.25B | Capitalization | 12.58B |
---|---|---|---|---|---|
Net income 2024 * | 180M | Net income 2025 * | 226M | EV / Sales 2024 * | 11 x |
Net Debt 2024 * | 166M | Net cash position 2025 * | 85.4M | EV / Sales 2025 * | 10 x |
P/E ratio 2024 * |
71.4
x | P/E ratio 2025 * |
57.4
x | Employees | - |
Yield 2024 * |
0.4% | Yield 2025 * |
0.4% | Free-Float | 99.03% |
Latest transcript on BIO-TECHNE Corp
Managers | Title | Age | Since |
---|---|---|---|
Kim Kelderman
CEO | Chief Executive Officer | 57 | 18-04-29 |
James Hippel
DFI | Director of Finance/CFO | 53 | 14-03-31 |
Matthew McManus
COO | Chief Operating Officer | 55 | Jan. 07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 02-12-31 | |
Charles Kummeth
BRD | Director/Board Member | 63 | 13-03-31 |
Randolph Steer
BRD | Director/Board Member | 74 | 89-12-31 |
1st Jan change | Capi. | |
---|---|---|
+21.87% | 47.96B | |
+0.78% | 42.45B | |
+43.96% | 41.47B | |
+26.26% | 31.6B | |
+20.87% | 28.63B | |
-4.47% | 28.03B | |
+52.11% | 14.56B | |
+45.42% | 14.14B | |
-4.54% | 11.71B |